Pediatrix Q3 2026 Earnings: Revenue Rises but Expense Pressure Weighs on EBITDA

Pediatrix Medical Group (NYSE: MD) reported Q3 2026 net revenue of $501.4 million, up 1.7% from $492.9 million, while diluted GAAP EPS declined to $0.59 from $0.84. Adjusted EPS rose to $0.72 from $0.67, but adjusted EBITDA slipped 2.1% as expenses at existing practices grew faster than revenue. Cash from continuing operations was $117.7 million, and full-year adjusted EBITDA guidance was $290 million to $300 million.

Core Earnings Data

Revenue growth came from both recent acquisitions and existing operations, but higher practice compensation and administrative expenses reduced operating leverage. Operating income and adjusted EBITDA declined despite the top-line increase.

GAAP comparisons were also affected by a $20.9 million gain on investments in divested businesses recorded in Q3 2025. Excluding specified items, adjusted income was nearly unchanged, while the lower diluted share count allowed adjusted EPS to increase.

Business and Volume Performance

Non-same-unit activity contributed 1.1 percentage points to revenue growth, reflecting recent acquisitions partly offset by practice dispositions. Same-unit revenue increased 0.6%, split evenly between a 0.3% contribution from reimbursement-related factors and a 0.3% contribution from patient volume.

Reimbursement benefited from a more favorable payor mix, higher administrative fees from hospital partners, and greater patient acuity, mainly in neonatology. Commercial and other non-government payors represented a share of services that was 70 basis points higher than a year earlier, although the comparison was partly offset by unusually strong cash-collection improvement in the prior-year quarter.

Volume trends were mixed. Office-based patient services increased 2.9%, while hospital-based services declined 0.3% and NICU days decreased 0.1%. These volume figures cover net patient service revenue and exclude contract and administrative fees.

Lower Share Count Lifted Adjusted EPS While Operating Profit Softened

Practice salaries and benefits increased approximately 2.8% to $341.5 million, while general and administrative expenses rose approximately 3.1% to $62.7 million. Both grew faster than the 1.7% increase in revenue. Management attributed the adjusted EBITDA decline primarily to expenses outpacing revenue growth at existing units, partly offset by favorable contributions from recent acquisitions.

Adjusted EBITDA margin was approximately 17.0%, compared with 17.7% a year earlier. At the same time, adjusted income was nearly flat at $57.2 million versus $57.5 million, but weighted average diluted shares declined approximately 6.9% to 79.7 million. That share-count reduction, primarily associated with the repurchase program, explains why adjusted EPS increased despite slightly lower adjusted income.

Cash Flow and Balance Sheet

Cash from continuing operations declined to $117.7 million from $138.1 million. After $4.4 million of capital expenditures, the company generated approximately $113.3 million of operating cash less capital expenditures before financing and other investing activities. Pediatrix used $83.0 million for share repurchases during the quarter.

Cash and cash equivalents were $311.9 million at September 30, down from $375.2 million at the end of 2025. Total debt, including finance leases on the balance sheet, declined to $577.7 million from $597.3 million. The company had no outstanding borrowings under its $450 million revolving credit facility.

2026 Guidance

Pediatrix provided a full-year 2026 adjusted EBITDA range of $290 million to $300 million. With $220.1 million generated during the first nine months, the outlook implies approximately $69.9 million to $79.9 million of adjusted EBITDA in the fourth quarter.

The source does not provide a previous guidance range, so the degree of any revision cannot be assessed.

Management View

CEO Mark S. Ordan said volume and pricing performed ahead of the company’s expectations. Management remains focused on operating efficiency and care quality while evaluating opportunities in adjacent businesses, but did not provide quantitative targets for those opportunities.

Recent Insider Transactions

The supplied six-month insider summary showed 472,100 shares categorized as purchases across 23 transactions and one sale of 36,028 shares, resulting in net purchases of 436,072 shares. However, the latest reported entries consisted mainly of stock awards and gifts, so the aggregate should not be interpreted as equivalent to open-market buying.

Risks Investors Should Watch

• Expense growth remains ahead of revenue: Practice compensation and G&A both increased faster than revenue, reducing operating and adjusted EBITDA margins.
• Underlying growth is modest: Same-unit revenue increased only 0.6%, while hospital-based volume and NICU days declined slightly.
• Acquisitions contributed more growth than same-unit operations: Non-same-unit activity accounted for 1.1 percentage points of the 1.7% revenue increase, and recent acquisitions also helped offset pressure on adjusted EBITDA.
• Cash conversion and guidance execution require monitoring: Operating cash flow declined year over year, while the full-year outlook requires fourth-quarter adjusted EBITDA of approximately $69.9 million to $79.9 million.

Summary

Pediatrix produced modest revenue growth and higher adjusted EPS in Q3 2026, supported by acquisitions, reimbursement factors, office-based volume, and a lower share count. The underlying operating picture was less favorable: expenses grew faster than revenue, adjusted EBITDA and margins declined, and hospital-based activity remained soft. Fourth-quarter expense control and delivery of the implied adjusted EBITDA needed to reach full-year guidance are the main items to monitor.